Kineta
Aims at developing edge therapeutics in autoimmune disease, viral disease, and chronic pain areas. Learn more
Launch date
Employees
Market cap
€8.6m
Enterprise valuation
€8m (Public information from Sep 2024)
Share price
$0.7 KA
Seattle Washington (HQ)
Authorizing premium user...